Kraj: Malezja
Język: angielski
Źródło: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
BUDESONIDE
ASTRAZENECA SDN. BHD.
BUDESONIDE
100Units Units
ASTRAZENECA AB
_ CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _ PULMICORT TURBUHALER Budesonide (100 mcg/dose & 200 mcg/dose) _ _ 1 WHAT IS IN THIS LEAFLET 1. What Pulmicort Turbuhaler is used for 2. How Pulmicort Turbuhaler works 3. Before you use Pulmicort Turbuhaler 4. How to use Pulmicort Turbuhaler 5. While you are using it 6. Side effects 7. Storage & Disposal of Pulmicort Turbuhaler 8. Product Description 9. Manufacturer & Product Registration Holder 10. Date of Revision READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. WHAT PULMICORT TURBUHALER IS USED FOR Pulmicort Turbuhaler is used for the regular treatment of asthma. _ _ HOW PULMICORT TURBUHALER WORKS Pulmicort Turbuhaler relieves and prevents inflammation in the airways caused by asthma. Pulmicort Turbuhaler is intended for regular use and not for rapid relief of acute asthma conditions. It may take some weeks before you receive the full effect of the treatment. BEFORE YOU USE PULMICORT TURBUHALER _- When you must not use it _ Do not use Pulmicort Turbuhaler if you are allergic (hypersensitive) to budesonide. _- Before you start to use it _ If you switch from cortisone tablets to Pulmicort Turbuhaler, as your previous allergic symptoms such as a runny nose and eczema may return in certain cases. You may also experience tiredness, headaches, muscle and joint pain and occasionally nausea and vomiting. This is because the total amount of cortisone in the body is reduced when the disease is treated locally in the lungs. These symptoms disappear after you have received treatment for some time. It is important that you tell your doctor if you Przeczytaj cały dokument
1 PULMICORT TURBUHALER 100 AND 200 MICROGRAMS/DOSE _BUDESONIDE _ Inhalation powder QUALITATIVE AND QUANTITATIVE COMPOSITION One metered dose contains budesonide 100 micrograms or 200 micrograms. PHARMACEUTICAL FORM Inhalation powder THERAPEUTIC INDICATIONS Bronchial asthma POSOLOGY AND METHOD OF ADMINISTRATION Posology The dosage of Pulmicort Turbuhaler is individual. Initially, at the beginning of inhaled corticosteroid therapy, for therapy during periods of severe asthma or when scaling down or withdrawing oral corticosteroids the dosage should be: _Paediatric Population _ _Children aged 5 – 7 years:_ 100 - 400 micrograms per day, divided into 2-4 inhalations. The full daily dose may be given in one administration. _Children aged 7 years and older:_ 100-800 micrograms per day, divided into 2-4 inhalations. With daily doses up to 400 micrograms the full dose may be given in one administration. _Adults:_ The normal dose range is 200-800 micrograms per day, divided into 2-4 inhalations. In more severe cases daily doses of up to 1600 micrograms may be needed. With daily doses up to 400 micrograms the full dose may be given in one administration. The maintenance dose should be the lowest possible. It is possible that the patient will not taste or perceive any medicine when Pulmicort Turbuhaler is used; this is because such a small amount of substance is dispensed. After a single dose an effect may be expected after a few hours. The full therapeutic effect is only achieved after several weeks of treatment. Treatment with Pulmicort Turbuhaler is a prophylactic therapy with no demonstrated effect on acute disorders. Clinical trials indicate that a larger amount of budesonide is deposited in the lungs when administered with Pulmicort Turbuhaler, compared with Pulmicort pMDI. If a patient in a stable phase is transferred from Pulmicort pMDI to Pulmicort Turbuhaler a reduction in dose may therefore be appropriate. In patients in whom an increased therapeutic effect is desired, on account of the lower risk of systemic si Przeczytaj cały dokument